| Title |
Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency
|
|---|---|
| Published in |
Research and Reports in Urology, October 2013
|
| DOI | 10.2147/rru.s38792 |
| Pubmed ID | |
| Authors |
Pamela Ellsworth, Mitchell Bamberger, Raymond Lee |
| Abstract |
Overactive bladder is a highly prevalent disorder with a significant impact on quality of life. Antimuscarinic agents are commonly used, but persistence is limited due to unsatisfactory efficacy and/or tolerability. Mirabegron is the first beta-3 adrenoceptor agonist approved for the treatment of overactive bladder syndrome. This paper reviews the pharmacology, mechanism of action, efficacy, and safety of mirabegron. A PubMed search of all English articles pertaining to mirabegron was performed. An alternative to antimuscarinics, mirabegron has a unique mechanism, improves overactive bladder symptoms and quality of life, and has limited adverse effects and few contraindications. |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 21 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 14% |
| Other | 2 | 10% |
| Professor > Associate Professor | 2 | 10% |
| Student > Master | 1 | 5% |
| Student > Bachelor | 1 | 5% |
| Other | 2 | 10% |
| Unknown | 10 | 48% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 29% |
| Nursing and Health Professions | 1 | 5% |
| Social Sciences | 1 | 5% |
| Sports and Recreations | 1 | 5% |
| Unknown | 12 | 57% |